Promising Biomarkers for Early Detection of Prostate Cancer Risk Identified

byColleen Fleisson August 18, 2023A cell metabolism process observed in males who have diabetes and metastatic prostate cancer holds the potential for future advancements in testing and tr

Updated on: December 19,2023

Promising Biomarkers for Early Detection of Prostate Cancer Risk Identified

byColleen Fleisson August 18, 2023A cell metabolism process observed in males who have diabetes and metastatic prostate cancer holds the potential for future advancements in testing and tr

Updated on:December 19,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on: December 25,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on:December 25,2023

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on: October 30,2023

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on:October 30,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on: October 24,2024

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on:October 24,2024

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on: November 14,2024

Patient-derived Organoids: Revolutionizing Cancer Research and Treatment

Updated on:November 14,2024

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on: January 28,2024

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on:January 28,2024

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on: December 21,2023

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on:December 21,2023

Study finds association between high insulin dosage and cancer

byOhio UniversityCredit: Unsplash/CC0 Public DomainDr. Yuanjie Mao has led a study published inJAMA Oncologylooking at the correlation between daily insulin dose and cancer incidence

Updated on: December 22,2023

Study finds association between high insulin dosage and cancer

byOhio UniversityCredit: Unsplash/CC0 Public DomainDr. Yuanjie Mao has led a study published inJAMA Oncologylooking at the correlation between daily insulin dose and cancer incidence

Updated on:December 22,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on: December 19,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on:December 19,2023